Value of pretreatment automated hemogram as a 5-year survival predictor in uterine cervical cancer clinical stage IIB-IVA
Descripción del Articulo
Objetive: To identify the value of the automated pretreatment blood count as a predictor of actuarial survival and 5-year disease-free actuarial survival in patients with clinical stage IIB-IVA cervical cancer. Material and Methods: Analysis of survival that evaluated 48 patients with pathologic dia...
Autores: | , |
---|---|
Formato: | artículo |
Fecha de Publicación: | 2021 |
Institución: | Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo |
Repositorio: | Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo |
Lenguaje: | español |
OAI Identifier: | oai:cmhnaaa_ojs_cmhnaaa.cmhnaaa.org.pe:article/872 |
Enlace del recurso: | https://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/872 |
Nivel de acceso: | acceso abierto |
Materia: | Sobrevida Neoplasias del Cuello Uterino Pronósticos Quimioradioterapia Survival Uterine Cervical Neoplasms Prognostic Chemoradiotherapy |
id |
REVCMH_286a831b6345077d3f630988fb9ee8ad |
---|---|
oai_identifier_str |
oai:cmhnaaa_ojs_cmhnaaa.cmhnaaa.org.pe:article/872 |
network_acronym_str |
REVCMH |
network_name_str |
Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo |
repository_id_str |
|
dc.title.none.fl_str_mv |
Value of pretreatment automated hemogram as a 5-year survival predictor in uterine cervical cancer clinical stage IIB-IVA Valor del hemograma automatizado pretratamiento como predictor de sobrevida a 5 años en cáncer de cuello uterino estadio clínico IIB – IVA |
title |
Value of pretreatment automated hemogram as a 5-year survival predictor in uterine cervical cancer clinical stage IIB-IVA |
spellingShingle |
Value of pretreatment automated hemogram as a 5-year survival predictor in uterine cervical cancer clinical stage IIB-IVA Luna-Abanto, Luciana Isabel Sobrevida Neoplasias del Cuello Uterino Pronósticos Quimioradioterapia Survival Uterine Cervical Neoplasms Prognostic Chemoradiotherapy |
title_short |
Value of pretreatment automated hemogram as a 5-year survival predictor in uterine cervical cancer clinical stage IIB-IVA |
title_full |
Value of pretreatment automated hemogram as a 5-year survival predictor in uterine cervical cancer clinical stage IIB-IVA |
title_fullStr |
Value of pretreatment automated hemogram as a 5-year survival predictor in uterine cervical cancer clinical stage IIB-IVA |
title_full_unstemmed |
Value of pretreatment automated hemogram as a 5-year survival predictor in uterine cervical cancer clinical stage IIB-IVA |
title_sort |
Value of pretreatment automated hemogram as a 5-year survival predictor in uterine cervical cancer clinical stage IIB-IVA |
dc.creator.none.fl_str_mv |
Luna-Abanto, Luciana Isabel Yan-Quiroz, Edgar Fermín |
author |
Luna-Abanto, Luciana Isabel |
author_facet |
Luna-Abanto, Luciana Isabel Yan-Quiroz, Edgar Fermín |
author_role |
author |
author2 |
Yan-Quiroz, Edgar Fermín |
author2_role |
author |
dc.subject.none.fl_str_mv |
Sobrevida Neoplasias del Cuello Uterino Pronósticos Quimioradioterapia Survival Uterine Cervical Neoplasms Prognostic Chemoradiotherapy |
topic |
Sobrevida Neoplasias del Cuello Uterino Pronósticos Quimioradioterapia Survival Uterine Cervical Neoplasms Prognostic Chemoradiotherapy |
description |
Objetive: To identify the value of the automated pretreatment blood count as a predictor of actuarial survival and 5-year disease-free actuarial survival in patients with clinical stage IIB-IVA cervical cancer. Material and Methods: Analysis of survival that evaluated 48 patients with pathologic diagnosis of clinical stage IIB-IVA cervical cancer treated with chemoradiotherapy treated at the Medical Oncology service at the Virgen de la Puerta High Complexity Hospital during the period 2015-2017. Results: The mean age of the patients was 51.78 ± 12.06 years (Range: 32-77 years). The average tumor size was 5.55 ± 1.33 cm (Range: 3 - 9 cm). Regarding the clinical stage according to the FIGO classification, it was found that 77.7% was classified as stage IIB, 20.8% as IIIB and 2.1% had a diagnosis of stage IVA cervical cancer. Univariate analysis found that anemia, leukocytosis, thrombocytosis, neutrophil / lymphocyte index, neutrophilia, and high platelet / lymphocyte index are not predictors of 5-year actuarial survival (p> 0.05), in terms of disease-free survival at 5 years it was found that anemia, leukocytosis and pretreatment neutrophil / lymphocyte index showed a trend towards significance (p = 0.05-0.1) and pretreatment neutrophilia is a predictor of 5-year disease-free survival, being statistically significant (0% vs 38.9%, p = 0.026). Conclusion: Pretreatment neutrophilia (> 7,500 μL) is a prognostic factor for 5-year disease-free survival in patients with clinical stage IIB-IVA cervical cancer undergoing chemoradiotherapy |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-05-21 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
https://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/872 10.35434/rcmhnaaa.2021.141.872 |
url |
https://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/872 |
identifier_str_mv |
10.35434/rcmhnaaa.2021.141.872 |
dc.language.none.fl_str_mv |
spa |
language |
spa |
dc.relation.none.fl_str_mv |
https://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/872/404 |
dc.rights.none.fl_str_mv |
Derechos de autor 2021 Luciana Isabel Luna-Abanto, Edgar Fermín Yan-Quiroz info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Derechos de autor 2021 Luciana Isabel Luna-Abanto, Edgar Fermín Yan-Quiroz |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Cuerpo Médico del Hospital Nacional Almanzor Aguinaga Asenjo |
publisher.none.fl_str_mv |
Cuerpo Médico del Hospital Nacional Almanzor Aguinaga Asenjo |
dc.source.none.fl_str_mv |
Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo; Vol. 14 No. 1 (2021): January - March; 40 - 47 Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo; Vol. 14 Núm. 1 (2021): Enero - Marzo; 40 - 47 2227-4731 2225-5109 reponame:Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo instname:Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo instacron:HNAAA |
instname_str |
Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo |
instacron_str |
HNAAA |
institution |
HNAAA |
reponame_str |
Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo |
collection |
Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo |
repository.name.fl_str_mv |
|
repository.mail.fl_str_mv |
|
_version_ |
1844532285346414592 |
spelling |
Value of pretreatment automated hemogram as a 5-year survival predictor in uterine cervical cancer clinical stage IIB-IVAValor del hemograma automatizado pretratamiento como predictor de sobrevida a 5 años en cáncer de cuello uterino estadio clínico IIB – IVALuna-Abanto, Luciana IsabelYan-Quiroz, Edgar FermínSobrevidaNeoplasias del Cuello UterinoPronósticosQuimioradioterapiaSurvivalUterine Cervical NeoplasmsPrognosticChemoradiotherapyObjetive: To identify the value of the automated pretreatment blood count as a predictor of actuarial survival and 5-year disease-free actuarial survival in patients with clinical stage IIB-IVA cervical cancer. Material and Methods: Analysis of survival that evaluated 48 patients with pathologic diagnosis of clinical stage IIB-IVA cervical cancer treated with chemoradiotherapy treated at the Medical Oncology service at the Virgen de la Puerta High Complexity Hospital during the period 2015-2017. Results: The mean age of the patients was 51.78 ± 12.06 years (Range: 32-77 years). The average tumor size was 5.55 ± 1.33 cm (Range: 3 - 9 cm). Regarding the clinical stage according to the FIGO classification, it was found that 77.7% was classified as stage IIB, 20.8% as IIIB and 2.1% had a diagnosis of stage IVA cervical cancer. Univariate analysis found that anemia, leukocytosis, thrombocytosis, neutrophil / lymphocyte index, neutrophilia, and high platelet / lymphocyte index are not predictors of 5-year actuarial survival (p> 0.05), in terms of disease-free survival at 5 years it was found that anemia, leukocytosis and pretreatment neutrophil / lymphocyte index showed a trend towards significance (p = 0.05-0.1) and pretreatment neutrophilia is a predictor of 5-year disease-free survival, being statistically significant (0% vs 38.9%, p = 0.026). Conclusion: Pretreatment neutrophilia (> 7,500 μL) is a prognostic factor for 5-year disease-free survival in patients with clinical stage IIB-IVA cervical cancer undergoing chemoradiotherapyObjetivo: Identificar el valor del hemograma automatizado pretratamiento como predictor de sobrevida actuarial y sobrevida actuarial libre de enfermedad a 5 años en pacientes con cáncer de cuello uterino estadio clínico IIB-IVA. Material y Métodos: Análisis de sobrevida que evaluó a 48 pacientes con diagnóstico anatomopatológico de cáncer de cuello uterino estadio clínico IIB-IVA tratadas con quimioradioterapia atendidas en el servicio de Oncología Médica en el Hospital de Alta Complejidad Virgen de la puerta durante el periodo 2015-2017. Resultados: La edad media de las pacientes fue 51,78 ± 12,06 años (Rango: 32-77 años). El tamaño tumoral promedio fue de 5,55 ± 1,33 cm (Rango: 3 – 9 cm). En cuanto al estadio clínico según la clasificación FIGO se encontró que el 77,7% fue catalogada como estadio IIB, 20,8% como IIIB y el 2,1% tuvo diagnóstico de cáncer de cérvix estadio IVA. En el análisis univariado se encontró que la anemia, leucocitosis, trombocitosis, índice neutrófilo/linfocito, neutrofilia e índice plaquetas/linfocitos alto no son predictores de sobrevida actuarial a 5 años (p>0,05), en cuanto a la sobrevida libre de enfermedad a 5 años se encontró que la anemia, leucocitosis e índice neutrófilo/linfocito pretratamiento presentaron una tendencia a la significancia (p=0,05-0,1) y la neutrofilia pretratamiento es un predictor de sobrevida libre de enfermedad a 5 años siendo estadísticamente significativo (0% vs 38,9%, p=0,026). Conclusión: La neutrofilia pretratamiento (>7500 μL) es un factor pronóstico de sobrevida libre de enfermedad a 5 años en pacientes con cáncer de cuello uterino estadio clínico IIB-IVA sometidas a quimioradioterapia.Cuerpo Médico del Hospital Nacional Almanzor Aguinaga Asenjo2021-05-21info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/87210.35434/rcmhnaaa.2021.141.872Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo; Vol. 14 No. 1 (2021): January - March; 40 - 47Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo; Vol. 14 Núm. 1 (2021): Enero - Marzo; 40 - 472227-47312225-5109reponame:Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjoinstname:Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjoinstacron:HNAAAspahttps://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/872/404Derechos de autor 2021 Luciana Isabel Luna-Abanto, Edgar Fermín Yan-Quirozinfo:eu-repo/semantics/openAccessoai:cmhnaaa_ojs_cmhnaaa.cmhnaaa.org.pe:article/8722022-02-01T00:21:01Z |
score |
13.408957 |
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).